Nanomedicine News

RSS

pSivida’s Nanotechnology-Based Tethadur Sustained-Release Delivery System to be Discussed at World Ophthalmology Conference

pSivida Corp. , a leader in the development of sustained release products for treating eye diseases, today announced that pSivida’s president and chief executive officer, Dr. Paul Ashton, will discuss pSivida’s Tethadur™ technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.

From EyePoint Pharmaceuticals, Inc. 2 Apr 2014

New Mechanism Utilizes Light to Activate Drug-Delivering Nanoparticles

Researchers from the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, in collaboration with materials scientists, engineers and neurobiologists, have discovered a new mechanism for using light to activate drug-delivering nanoparticles and other targeted therapeutic substances inside the body.

2 Apr 2014

NanoViricides’ President Honored as ‘Researcher of the Year’

NanoViricides, Inc. (the “Company”) announced today that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the “2014 Researcher of the Year” by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut.

From NanoViricides, Inc 1 Apr 2014

Enrollment Begins for MF 1001 NanoTherm Therapy Study for Glioblastoma Treatment

MagForce AG (Frankfurt, Xetra: MF6), a leading medical technology company in the area of nanotechnology which focuses on oncology, today announced the enrollment of the first patient in the MF 1001 clinical study. MF 1001 is an open-label, randomized, controlled clinical trial assessing the efficacy and safety of NanoTherm® therapy as monotherapy and in combination with radiotherapy compared to radiotherapy alone in glioblastoma patients at first relapse.

From MagForce Nanotechnologies AG 1 Apr 2014

Merrimack to Present Posters on Nanoliposomal Irinotecan at 2014 AACR Annual Meeting

Merrimack Pharmaceuticals, Inc. today announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol* as an MRI imaging agent prior to MM-398 investigational treatment.

1 Apr 2014

Researchers Find Unique Pattern in Leukemia Cells Using Microarray Technology

Nearly half of patients with the most common form of adult leukemia are said to have normal chromosomes but appear instead to have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment, researchers report.

31 Mar 2014

Celator Begins Clinical Study of CPX-351 in High Risk MDS and AML Patients

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection as a treatment for patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), who are refractory to or in relapse after hypomethylating agent (HMA) therapy.

28 Mar 2014

TSRI Scientists Develop Method of Modifying Organic Molecules for Improving Medical Care

Advancements targeted to improving medical care continue to provide tools that could advance development of high throughput atomically precise manufacturing. In the latest example, chemists have developed a method to add a functional group to a specific carbon atom several atoms away from a given atom.

28 Mar 2014

Australia and the Philippines Award Fundamental Patents to NanoViricides

NanoViricides, Inc. (the "Company"), announced today that a fundamental PCT patent application, on which the nanoviricides® technology is based, has resulted in additional issued patents in Australia and the Philippines.

From NanoViricides, Inc 25 Mar 2014

Comprehensive Report Analyzes Worldwide Markets for Nanotechnology in Drug Delivery

Research and Markets has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering.

From Research and Markets 25 Mar 2014

Nanomedicine News

pSivida’s Nanotechnology-Based Tethadur Sustained-Release Delivery System to be Discussed at World Ophthalmology Conference

New Mechanism Utilizes Light to Activate Drug-Delivering Nanoparticles

NanoViricides’ President Honored as ‘Researcher of the Year’

Enrollment Begins for MF 1001 NanoTherm Therapy Study for Glioblastoma Treatment

Merrimack to Present Posters on Nanoliposomal Irinotecan at 2014 AACR Annual Meeting

Researchers Find Unique Pattern in Leukemia Cells Using Microarray Technology

Celator Begins Clinical Study of CPX-351 in High Risk MDS and AML Patients

TSRI Scientists Develop Method of Modifying Organic Molecules for Improving Medical Care

Australia and the Philippines Award Fundamental Patents to NanoViricides

Comprehensive Report Analyzes Worldwide Markets for Nanotechnology in Drug Delivery

Scientists Create the Largest Atomically Thin Gold Films to Make Electronics Weightless and Invisible

Chiral Textures in Ferroelectric Nanoislands

Engineered DNA-Nanoparticle Motors Achieve Motor Protein Speeds

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Sustainable Future for Carbon Nanotubes

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials